- PM13: Ocular Toxicity of Systemically Administered Therapeutics
-
Primary Endorser: Ocular Toxicology Specialty Section
Endorser(s): Biotechnology Specialty Section
This course will provide a multi-perspective examination of ocular toxicity associated with systemically administered therapeutics, with an emphasis on the translational link between nonclinical findings and clinical risk. As oncology and immunology drug discovery increasingly identifies new targets through genomics, transcriptomics, and proteomics, the potential for unintended effects on visual function has become an important safety consideration. Some of these targets and therapeutic modalities have demonstrated ocular liability, underscoring the need to integrate omics, toxicology, pathology, and clinical observation to better characterize risk and inform drug development decisions.
The course will begin with a toxicological perspective on the ocular endpoints most relevant for risk evaluation in drug development, including key regulatory expectations for ocular safety assessment and study design. Emphasis will be placed on oncology targets such as Mitogen Activating Protein Kinase (MAPK) Pathway, MERTK, and Anaplastic Lymphoma Kinase (ALK), and on modalities such as antibody-drug conjugates (ADCs) and antibodies, which may affect different parts of the eye through distinct mechanisms. Bioinformatics and in silico approaches will also be considered in the context of target biology and adverse effect prediction, providing attendees with a framework for identifying ocular safety liabilities earlier in development. Translational and clinical case studies will then illustrate how agents such as ADCs, ALK inhibitors, anti-MERTK mAbs, and MEK inhibitors have been associated with undesirable effects in the visual system and/or ocular toxicities across nonclinical studies and clinical use, highlighting the importance of integrating emerging signals into development strategy and clinical risk translation and mitigation.
A central theme of the course will be the evaluation of structure-function relationships using in vivo ophthalmic endpoints in nonclinical and clinical settings and their correlation with histopathology findings. Historically used in ocular toxicity studies for ophthalmic drugs and biologics, these endpoints are increasingly relevant to oncology and immunology programs and may be unfamiliar to general toxicologists. The course will highlight key ophthalmic assessments, pathology, and emerging molecular and spatial approaches that together support baseline screening, investigative toxicology, and a more integrated understanding of ocular findings in systemically administered therapeutics. Together, these presentations will provide attendees with a framework for ocular safety assessment of systemically administered therapeutics and will strengthen hazard identification, mechanistic interpretation, translational planning, and clinical decision-making in oncology and immunology drug development.Session and Activity Type
Enter Note
Go to previous page in this tab
Event
